Zacks Investment Research Downgrades Motus GI (NASDAQ:MOTS) to Sell

Share on StockTwits

Motus GI (NASDAQ:MOTS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Zacks.com reports.

According to Zacks, “Motus GI Holdings, Inc. is a medical technology company. It focuses on the development and commercialization of the Pure-Vu(R) System to improve the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon. The company also operates through subsidiaries in the U.S. and Israel. Motus GI Holdings, Inc. is based in FL, United States. “

Other research analysts have also issued reports about the stock. Piper Jaffray Companies reduced their target price on shares of Motus GI from $8.00 to $6.00 in a report on Friday, May 10th. Oppenheimer set a $10.00 target price on shares of Motus GI and gave the company a “buy” rating in a report on Thursday, March 28th. Finally, ValuEngine lowered shares of Zumiez from a “hold” rating to a “sell” rating in a report on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $8.60.

NASDAQ:MOTS traded down $0.01 during trading hours on Wednesday, reaching $2.97. The company had a trading volume of 91,034 shares, compared to its average volume of 263,714. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.31 and a current ratio of 6.36. Motus GI has a 52 week low of $2.34 and a 52 week high of $7.95. The stock has a market cap of $63.92 million, a price-to-earnings ratio of -2.41 and a beta of 1.61. The company’s 50 day simple moving average is $3.38.

Motus GI (NASDAQ:MOTS) last posted its earnings results on Friday, May 10th. The company reported ($0.29) EPS for the quarter, hitting analysts’ consensus estimates of ($0.29). On average, equities research analysts predict that Motus GI will post -1.14 earnings per share for the current year.

In other news, major shareholder Life Sciences Maste Perceptive acquired 1,000,000 shares of the stock in a transaction on Thursday, June 27th. The stock was bought at an average price of $3.00 per share, with a total value of $3,000,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman David P. Hochman acquired 10,000 shares of the stock in a transaction on Monday, July 1st. The stock was purchased at an average cost of $3.00 per share, with a total value of $30,000.00. The disclosure for this purchase can be found here. Insiders acquired 2,059,332 shares of company stock valued at $6,179,896 in the last ninety days. 18.14% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the business. RTW Investments LP lifted its stake in Motus GI by 672.5% during the fourth quarter. RTW Investments LP now owns 459,478 shares of the company’s stock worth $1,429,000 after purchasing an additional 400,000 shares during the last quarter. Mesirow Financial Investment Management Inc. lifted its stake in Motus GI by 69.2% in the second quarter. Mesirow Financial Investment Management Inc. now owns 151,866 shares of the company’s stock valued at $480,000 after buying an additional 62,112 shares during the last quarter. Finally, Spark Investment Management LLC lifted its stake in Motus GI by 73.5% in the first quarter. Spark Investment Management LLC now owns 28,900 shares of the company’s stock valued at $112,000 after buying an additional 12,245 shares during the last quarter. 35.30% of the stock is owned by institutional investors.

About Motus GI

Motus GI Holdings, Inc operates as a medical technology company to enhance the endoscopy outcomes and experiences in the United States and Israel. It focuses on the development and commercialization of the Pure-Vu system to enhance the colonoscopy experience and assist in the early detection and prevention of colorectal cancer and other diseases of the rectum and colon.

Read More: What are momentum indicators and what do they show?

Get a free copy of the Zacks research report on Motus GI (MOTS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.